on Jaguar Health, Inc. (NASDAQ:JAGX)
Jaguar Health's Q2 2025 Financial Growth and Future Plans
San Francisco-based Jaguar Health, Inc. reported a 35% increase in net revenue for Q2 2025, reaching approximately $3.0 million compared to $2.2 million in Q1 2025. This significant growth also reflects a 10% rise over the same period in 2024. A notable increase was observed in the Mytesi prescription volume by 6.5% in Q2 2025 compared to Q1 2025, maintaining the same level as Q2 2024.
The company emphasized advancements in their research with positive proof-of-concept results for their product crofelemer. Their regulatory path plans to include patients with metastatic breast cancer, aligned with orphan drug criteria in the US. Jaguar Health's strategy remains focused on seeking partnerships for non-dilutive funding through licensing its orphan indication products. A webcast will be held to discuss these updates and their financial results.
R. H.
Copyright © 2025 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all Jaguar Health, Inc. news